<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070642</url>
  </required_header>
  <id_info>
    <org_study_id>C023</org_study_id>
    <secondary_id>CO23, A8501023</secondary_id>
    <nct_id>NCT00070642</nct_id>
  </id_info>
  <brief_title>CPG 7909 Injection in Melanoma</brief_title>
  <official_title>ProMuneâ„¢ (CPG 7909 Injection) With or Without Chemotherapy for the Treatment of Stage III b/c or IV Melanoma: A Randomized, Multi-Center, Open Label, Parallel Group, Active-Controlled, Phase II/III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given
      with chemotherapy to patients with melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase II: Assess the anti-neoplastic activity, as determined by overall response rate (complete plus partial responses) according to the RECIST criteria.</measure>
    <time_frame>indeterminate</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III: Evaluate and compare the survival time of the two treatment groups, as selected in Phase II.</measure>
    <time_frame>Indeterminate</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase III: Assess the overall response rate</measure>
    <time_frame>indeterminate</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asses the degree of clinical benefit defined as the proportion of patients experiencing complete and partial responses as well as stable disease.</measure>
    <time_frame>indeterminate</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the duration of response.</measure>
    <time_frame>indeterminate</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the time to progression</measure>
    <time_frame>indeterminate</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetic profile and immunopharmacodynamic response to CPG 7909 Injection alone or in combination with DTIC, or DTIC alone (immunopharmacodynamic response only).</measure>
    <time_frame>indeterminate</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the tolerability of CPG 7909 Injection alone, CPG 7909 Injection in combination with DTIC vs. DTIC alone</measure>
    <time_frame>indeterminate</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Carcinoma, Melanoma</condition>
  <arm_group>
    <arm_group_label>CPG 7909 Injection plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPG 7909 Injection plus DTIC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dacarbazine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPG 7909 Injection 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CPG 7909 Injection 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG 7909 Injection</intervention_name>
    <description>CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.</description>
    <arm_group_label>CPG 7909 Injection plus chemotherapy</arm_group_label>
    <other_name>ProMune, PF-3512676</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dacarbazine</intervention_name>
    <description>dacarbazine 850mg/m2 in three-week cycles until disease progression</description>
    <arm_group_label>CPG 7909 Injection plus chemotherapy</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy in three-week cycles until disease progression:
dacarbazine 850mg/m2</description>
    <arm_group_label>Chemotherapy alone</arm_group_label>
    <other_name>DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG 7909 Injection</intervention_name>
    <description>CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.</description>
    <arm_group_label>CPG 7909 Injection 10 mg</arm_group_label>
    <other_name>ProMune, PF-03512676</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPG 7909 Injection</intervention_name>
    <description>CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.</description>
    <arm_group_label>CPG 7909 Injection 40 mg</arm_group_label>
    <other_name>ProMune, PF-03512676</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed melanoma that is metastatic.

          -  Measurable disease according to the RECIST criteria.

          -  Karnofsky Performance Status of &gt; 70.

        Exclusion Criteria:

          -  Prior treatment with anti-neoplastic biologic or chemotherapy for recurrent or
             metastatic disease (except one course of adjuvant immunotherapy and/or adjuvant
             chemotherapy other than DTIC).

          -  Suspected or known CNS metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=CO23&amp;StudyName=CPG%207909%20Injection%20in%20Melanoma</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2003</study_first_submitted>
  <study_first_submitted_qc>October 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2003</study_first_posted>
  <last_update_submitted>February 9, 2009</last_update_submitted>
  <last_update_submitted_qc>February 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Immunotherapy, skin cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

